Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068302 | 0.83 | GAA (0.48) | ALDH1A1KMT2AMEN1LMNAGAA | |
| Ammonia Solution, Strong SCHEMBL9774304 | 0.81 | GAA (0.47) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL5320949 | 0.81 | HTT (0.42) | ALDH1A1KDM4EGAA | |
| SCHEMBL660307 | 0.77 | GAA (0.43) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL8997420 | 0.74 | HTT (0.35) | MAPTLMNAGAA | |
| Inositol Niacinate SCHEMBL122590 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KMT2AL3MBTL1MAPTKDM4E | |
| Inositol Niacinate SCHEMBL122591 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KMT2AL3MBTL1MAPTKDM4E | |
| Inositol Niacinate SCHEMBL29499769 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KMT2AL3MBTL1MAPTKDM4E | |
| Inositol Niacinate SCHEMBL13557040 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KMT2AL3MBTL1MAPTKDM4E | |
| SCHEMBL21243069 | 0.73 | ALDH1A1 (0.59) | ALDH1A1KMT2AL3MBTL1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403300-B1 | Polyisocyanate resins | LANXESS DEUTSCHLAND GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1403300-A1 | Polyisocyanate resins | Bayer Chemicals AG (DE) | 2004-03-31 | — | — | EP | claimed |
| EP-3047277-A1 | AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER | Adelaide Research & Innovation Pty Ltd. (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039175-A1 | AUTOANTIBODY BIOMARKERS OF OVARIAN CANCER | ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) | 2015-03-26 | — | — | WO | disclosed |
| WO-2010109022-A1 | QUANTITATIVE PROTEOMICS METHOD | UNIVERSITETET I OSLO (NO) | 2010-09-30 | — | — | WO | disclosed |
| EP-1392848-B1 | PROCESS FOR ANALYZING PROTEIN SAMPLES | PERSEPTIVE BIOSYSTEMS INC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1403300-B1 | Polyisocyanate resins | LANXESS DEUTSCHLAND GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-7045296-B2 | Process for analyzing protein samples | APPLERA CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050196823-A1 | Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore | PRONOTA NV (BE) | 2005-09-08 | — | — | US | disclosed |
| EP-1392848-A4 | PROCESS FOR ANALYZING PROTEIN SAMPLES | PERSEPTIVE BIOSYSTEMS INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6908740-B2 | Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore | MYCARTIS NV (BE) | 2005-06-21 | — | — | US | disclosed |
| EP-1403300-A1 | Polyisocyanate resins | Bayer Chemicals AG (DE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | disclosed |
| EP-1392848-A2 | PROCESS FOR ANALYZING PROTEIN SAMPLES | PerSeptive Biosystems, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040005633-A1 | Methods and apparatuses for gel-free qualitative and quantitative proteome analysis, and uses therefore | MYCARTIS NV (BE) | 2004-01-08 | — | — | US | disclosed |
| EP-1370571-A2 | METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFOR | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| US-20020192720-A1 | Process for analyzing protein samples | APPLIED BIOSYSTEMS, LLC | 2002-12-19 | — | — | US | disclosed |
| WO-2002090929-A2 | PROCESS FOR ANALYZING PROTEIN SAMPLES | PERSEPTIVE BIOSYSTEMS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002077016-A2 | METHODS AND APPARATUS FOR GEL-FREE QUALITATIVE AND QUANTITATIVE PROTEOME ANALYSIS, AND USES THEREFORE | VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (BE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040005633-A1 | Methods and apparatuses for gel-free qualitative and quantitative proteome analysis, and uses therefore | PTMS, ANPEP, DNPEP | ALDH1A1 4642/4885KMT2A 4044/4885L3MBTL1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.